Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rutger M. van den Bor"'
Autor:
Els van der Heijden, Rutger M. van den Bor, Cornelis K. van der Ent, Sanne L. Nijhof, Sabine E.I. van der Laan
Publikováno v:
ERJ Open Research, Vol 9, Iss 3 (2023)
Introduction For people with cystic fibrosis (CF), gaining access to elexacaftor/tezacaftor/ivacaftor (ETI) therapy, a new modulator drug combination, is perceived as a positive life event. ETI leads to a strong improvement of disease symptoms. Howev
Externí odkaz:
https://doaj.org/article/8837cac708614d0283ec51de6a5e9525
Autor:
Rutger M. van den Bor, Diederick E. Grobbee, Bas J. Oosterman, Petrus W.J. Vaessen, Kit C.B. Roes
Publikováno v:
Contemporary Clinical Trials Communications, Vol 7, Iss , Pp 208-216 (2017)
Failure to meet subject recruitment targets in clinical trials continues to be a widespread problem with potentially serious scientific, logistical, financial and ethical consequences. On the operational level, enrollment-related issues may be mitiga
Externí odkaz:
https://doaj.org/article/1ea29a474bec430685ab0c67821948db
Autor:
Arno W Hoes, Frans H Rutten, Menno V Huisman, Geert-Jan Geersing, Linda P T Joosten, Sander van Doorn, Melchior C Nierman, Nynke M Wiersma, Huiberdina L Koek, Martin E W Hemels, Kit C Roes, Rutger M van den Bor, Wim F Buding
Publikováno v:
BMJ Open, Vol 9, Iss 12 (2019)
Introduction Clinical guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF). Frail elderly were under-represented in the landma
Externí odkaz:
https://doaj.org/article/6f52ec45918b42bb88865eb7646f4c18
Autor:
Bas J. Oosterman, Petrus W.J. Vaessen, Diederick E. Grobbee, Kit C.B. Roes, Rutger M. van den Bor
Publikováno v:
Contemporary Clinical Trials Communications, Vol 7, Iss, Pp 208-216 (2017)
Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications, 7, 208. Elsevier Inc.
Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications, 7, 208. Elsevier Inc.
Failure to meet subject recruitment targets in clinical trials continues to be a widespread problem with potentially serious scientific, logistical, financial and ethical consequences. On the operational level, enrollment-related issues may be mitiga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d0585cf093bb443a55a7b804bd1519
http://www.sciencedirect.com/science/article/pii/S2451865417300297
http://www.sciencedirect.com/science/article/pii/S2451865417300297
Autor:
Diederick E. Grobbee, Rutger M. van den Bor, Kit C.B. Roes, Bas J. Oosterman, Martinus B. Oostendorp
Publikováno v:
Therapeutic Innovation and Regulatory Science, 50(1), 82. SAGE Publications Inc.
Background: One approach to increase the efficiency of clinical trial monitoring is to replace 100% source data verification (SDV) by verification of samples of source data. An intuitive strategy for determining appropriate sampling plans (ie, sample
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40aac322c8f1d1dde7e7ad419dae9c46
https://dspace.library.uu.nl/handle/1874/333446
https://dspace.library.uu.nl/handle/1874/333446
